Peripheral and Central Administration of Soluble Glycoprotein 130 Improves Cognitive Outcomes Following Controlled Cortical Impact in Male Mice
Open Access
- 1 January 2026
- journal article
- research article
- Published by SAGE Publications in Neurotrauma Reports
- Vol. 7
Abstract
Traumatic brain injury (TBI) initiates complex immune responses, including upregulation of interleukin (IL)−6, a cytokine associated with clinical outcomes after injury. IL-6 trans-signaling, via the solubilized IL-6 receptor, drives pro-inflammatory cascades and is selectively inhibited by soluble glycoprotein 130 (sgp130). Although chronic intermittent sgp130Fc fusion protein (sgp130Fc) treatment after TBI has shown benefits across species, optimal dosing remains unclear. This study evaluated the effects of a single sgp130Fc dose (2 μg intrahippocampally or 10 μg intraperitoneally) in male mice on day three following controlled cortical impact or sham procedures. Cognitive performance was assessed using the Morris water maze, and histological assessment included lesion volume and microglia quantification. Intrahippocampal sgp130Fc improved spatial memory during probe trials, decreasing latency to the platform zone ( p < 0.05) and enhanced spatial swim strategy selection ( p < 0.05). Intraperitoneal sgp130Fc improved spatial learning ( p < 0.05) and reduced anxiety-like behavior, indicated by increased target zone time during probe trials and decreased peripheral zone time ( p < 0.05). Neither route significantly altered lesion volume or thalamic ionized calcium-binding adaptor molecule 1+ cell counts versus vehicle-treated injured animals; however, intrahippocampal sgp130Fc reduced major histocompatibility complex class II+ cells. These findings demonstrate that a single subacute sgp130Fc dose confers modest behavioral benefits when administered post-TBI, without worsening outcomes. The results underscore the effects of IL-6 trans-signaling inhibition on TBI outcomes and highlight the need for further research into dose, timing, and sex-specific responses. Overall, these data add to emerging support that selective IL-6 blockade with sgp130Fc may represent a translatable strategy to modulate post-TBI inflammation and support cognitive recovery, in part, via reducing anxiety-associated dysfunction.Keywords
Funding Information
- Congressionally Directed Medical Research Programs (W81XWH-22-2-0056)
- University of Pittsburgh Medical Center Rehabilitation Institute
This publication has 58 references indexed in Scilit:
- Effect of Induction Therapy With Olamkicept vs Placebo on Clinical Response in Patients With Active Ulcerative ColitisJAMA, 2023
- Role of interleukin-6-mediated inflammation in the pathogenesis of inflammatory bowel disease: focus on the available therapeutic approaches and gut microbiomeJournal of Cell Communication and Signaling, 2022
- Repopulating Microglia Promote Brain Repair in an IL-6-Dependent MannerCell, 2020
- Neuroinflammation and blood–brain barrier disruption following traumatic brain injury: Pathophysiology and potential therapeutic targetsJournal of Neuroscience Research, 2018
- Sexual dimorphism in the inflammatory response to traumatic brain injuryGlia, 2017
- The role of interleukin-6 signaling in nervous tissueBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2016
- Inflammation and Neuroprotection in Traumatic Brain InjuryJAMA Neurology, 2015
- Acute CSF interleukin-6 trajectories after TBI: Associations with neuroinflammation, polytrauma, and outcomeBrain, Behavior, and Immunity, 2015
- Variable neuroendocrine–immune dysfunction in individuals with unfavorable outcome after severe traumatic brain injuryBrain, Behavior, and Immunity, 2015
- The pro- and anti-inflammatory properties of the cytokine interleukin-6Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2011